News Details

WALTHAM, Mass. – PerkinElmer Life and Analytical Sciences, a global leader in application-focused measurement and analysis solutions, today introduced the Spectrum^™ 100 Optica, the only commercially available Fournier Transform Infrared (FT-IR) spectrometer developed specifically for the optical filters and coatings industry.

The robust instrument provides improved ordinate accuracy for the measurement of optical filters and high refractive index materials. Manufacturers of optical filters and specialty coatings can use the Spectrum 100 Optica to validate the performance specifications of these materials to block or transmit IR radiation. This validation is critical in both quality assurance/quality control (QA/QC) and research and development of filters and coatings. The components are then used in various industries, including defense and aviation, in such products as remote control units, security systems, sensors, scanners and IR cameras. The Spectrum^™ 100 Optica can also be used by academic researchers to study the transmission properties of high refractive index materials.

“We used our extensive experience in the optical industry to design an instrument that maintains the high level of accuracy our customers obtain from traditional dispersive IR technology,” said Jerry Sellors, IR Technology Manager, Molecular Spectroscopy, PerkinElmer Life and Analytical Sciences. “The Spectrum^™ 100 Optica is custom-built for the optical industry with components that overcome the challenges inherent with the use of standard IR for these measurements.”

The Spectrum^™ 100 Optica features optical modification, advanced signal processing and special detector considerations all designed to address the major instrument problems associated with FT-IR measurement of optical materials.

PerkinElmer has verified the Spectrum^™ 100 Optica against the National Institute of Standards and Technology (NIST) standards and employs additional accuracy checks in the manufacturing facility before the instrument is delivered to the customer.

For more information, visit www.perkinelmer.com/spectrum100optica.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.8 billion in 2007, has 9,100 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE-877-PKI-NYSE.

For further information regarding PerkinElmer, please contact:

Media Contact:
Ellen Wein
(412) 456-0986
or
Lesley Sillaman
(412) 456-7839